Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Pletal
Cilostazol is a vasodilator that inhibits platelet aggregation and is primarily used to treat intermittent claudication, a symptom of peripheral artery disease (PAD). It belongs to the class of phosphodiesterase 3 (PDE3) inhibitors. By widening blood vessels and preventing blood clots, cilostazol improves blood flow to the legs and reduces pain and cramping associated with PAD.
Used to treat intermittent claudication symptoms associated with peripheral artery disease (PAD).
Outcome:
Increased cilostazol levels and risk of side effects.
Mechanism:
Inhibition of CYP3A4 metabolism.
Outcome:
Increased cilostazol levels.
Mechanism:
CYP3A4 inhibition.
Outcome:
Increased risk of bleeding.
Mechanism:
Additive antiplatelet effects.
Most likely new formulation: Extended-release formulation to improve patient compliance (Year: 2026, 30% confidence)
Based on current usage trends and clinical trial data, there is a low likelihood (<5%) of cilostazol being withdrawn from the market in the next 5 years.
Vasodilator, Antiplatelet Agent, Phosphodiesterase 3 Inhibitor
Quinolinone